ProCE Banner Activity

ECOG-ACRIN 2108: Phase III Trial Evaluating the Role of Early Local Therapy for Patients With Metastatic Breast Cancer and an Intact Primary Tumor

Slideset Download
Conference Coverage
Addition of early local therapy to systemic therapy for intact primary tumors in patients with de novo MBC was not associated with a survival benefit vs continued systemic therapy alone.

Released: June 09, 2020

Expiration: June 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono